<?xml version='1.0' encoding='utf-8'?>
<document id="29283173"><sentence text="CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats."><entity charOffset="69-79" id="DDI-PubMed.29283173.s1.e0" text="triptolide" /></sentence><sentence text="Triptolide is the most active ingredient of Tripterygium wilfordii Hook F, which is used to treat rheumatoid arthritis"><entity charOffset="0-10" id="DDI-PubMed.29283173.s2.e0" text="Triptolide" /></sentence><sentence text=" (5R)-5-Hydroxytriptolide is a hydroxylation derivative of triptolide with a reduced toxicity"><entity charOffset="1-25" id="DDI-PubMed.29283173.s3.e0" text="(5R)-5-Hydroxytriptolide" /><entity charOffset="59-69" id="DDI-PubMed.29283173.s3.e1" text="triptolide" /><pair ddi="false" e1="DDI-PubMed.29283173.s3.e0" e2="DDI-PubMed.29283173.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s3.e0" e2="DDI-PubMed.29283173.s3.e1" /></sentence><sentence text=" To investigate the metabolic enzymes of the two compounds and the drug-drug interactions with enzyme inducers or inhibitors, a series of in vitro and in vivo experiments were conducted" /><sentence text=" In vitro studies using recombinant human cytochrome P450 enzyme demonstrated that cytochrome P450 3A4 (CYP3A4) was predominant in the metabolism of triptolide and (5R)-5-hydroxytriptolide, accounting for 94"><entity charOffset="149-159" id="DDI-PubMed.29283173.s5.e0" text="triptolide" /><entity charOffset="164-188" id="DDI-PubMed.29283173.s5.e1" text="(5R)-5-hydroxytriptolide" /><pair ddi="false" e1="DDI-PubMed.29283173.s5.e0" e2="DDI-PubMed.29283173.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s5.e0" e2="DDI-PubMed.29283173.s5.e1" /></sentence><sentence text="2% and 64" /><sentence text="2% of the metabolism, respectively" /><sentence text=" Pharmacokinetics studies were conducted in male SD rats following administration of triptolide or (5R)-5-hydroxytriptolide (0"><entity charOffset="85-95" id="DDI-PubMed.29283173.s8.e0" text="triptolide" /><entity charOffset="99-123" id="DDI-PubMed.29283173.s8.e1" text="(5R)-5-hydroxytriptolide" /><pair ddi="false" e1="DDI-PubMed.29283173.s8.e0" e2="DDI-PubMed.29283173.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s8.e0" e2="DDI-PubMed.29283173.s8.e1" /></sentence><sentence text="4 mg/kg, po)" /><sentence text=" The plasma exposure to triptolide and (5R)-5-hydroxytriptolide in the rats was significantly increased when co-administered with the CYP3a inhibitor ritonavir (30 mg/kg, po) with the values of AUC0-∞ (area under the plasma concentration-time curve from time zero extrapolated to infinity) being increased by 6"><entity charOffset="24-34" id="DDI-PubMed.29283173.s10.e0" text="triptolide" /><entity charOffset="39-63" id="DDI-PubMed.29283173.s10.e1" text="(5R)-5-hydroxytriptolide" /><entity charOffset="150-159" id="DDI-PubMed.29283173.s10.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.29283173.s10.e0" e2="DDI-PubMed.29283173.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s10.e0" e2="DDI-PubMed.29283173.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29283173.s10.e0" e2="DDI-PubMed.29283173.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29283173.s10.e1" e2="DDI-PubMed.29283173.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29283173.s10.e1" e2="DDI-PubMed.29283173.s10.e2" /></sentence><sentence text="84 and 1" /><sentence text="83 times, respectively" /><sentence text=" When pretreated with the CYP3a inducer dexamethasone (50 mg·kg-1·d-1, for 3 d), the AUC0-∞ values of triptolide and (5R)-5-hydroxytriptolide were decreased by 85"><entity charOffset="40-53" id="DDI-PubMed.29283173.s13.e0" text="dexamethasone" /><entity charOffset="102-112" id="DDI-PubMed.29283173.s13.e1" text="triptolide" /><entity charOffset="117-141" id="DDI-PubMed.29283173.s13.e2" text="(5R)-5-hydroxytriptolide" /><pair ddi="false" e1="DDI-PubMed.29283173.s13.e0" e2="DDI-PubMed.29283173.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s13.e0" e2="DDI-PubMed.29283173.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29283173.s13.e0" e2="DDI-PubMed.29283173.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29283173.s13.e1" e2="DDI-PubMed.29283173.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29283173.s13.e1" e2="DDI-PubMed.29283173.s13.e2" /></sentence><sentence text="4% and 91" /><sentence text="4%, respectively" /><sentence text=" These results suggest that both triptolide and (5R)-5-hydroxytriptolide are sensitive substrates of CYP3a"><entity charOffset="33-43" id="DDI-PubMed.29283173.s16.e0" text="triptolide" /><entity charOffset="48-72" id="DDI-PubMed.29283173.s16.e1" text="(5R)-5-hydroxytriptolide" /><pair ddi="false" e1="DDI-PubMed.29283173.s16.e0" e2="DDI-PubMed.29283173.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29283173.s16.e0" e2="DDI-PubMed.29283173.s16.e1" /></sentence><sentence text=" Because of their narrow therapeutic windows, clinical drug-drug interaction studies should be carried out to ensure their clinical medication safety and efficacy" /><sentence text="" /></document>